VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 26, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that Verisante Aura™, a non-invasive skin cancer detection device, was voted a Bronze Edison Award winner for innovation at the April 25th event at Navy Pier in Chicago.
"Our judges recognized Aura™ as a true innovator out of the many products in its category," said Frank Bonafilia, executive director of the Edison Awards.
Being recognized with an Edison Award has become one of the highest accolades a company can receive in the name of innovation and business. The awards are named after Thomas Alva Edison (1847-1931) whose inventions, new product development methods and innovative achievements literally changed the world, garnered him 1,093 U.S. patents, and made him a household name around the world.
"We are humbled and honoured to win the Edison Award," said Thomas Braun, President & CEO, Verisante Technology, Inc., who joined hundreds of senior executives from some of the world's most recognized companies to accept the award. "This is the first time that we have an objective tool that provides a scientific measurement of a lesion to help dermatologists make a biopsy decision. None of this would be possible without the tireless efforts of our scientists and staff who pioneered a better way to diagnose skin cancer for significantly improved patient outcomes."
The clinical study results of Aura™ were published last year in the peer-reviewed journal, Cancer Research and showed that the device provides a significant advancement over current clinical diagnosis. The study results showed that Aura™ had a success rate of 99 per cent in finding skin cancer and the potential to reduce unnecessary biopsies by 50 to 100 per cent.
The ballot of nominees for the Edison Awards™ was judged by a panel of more than 3,000 leading business executives including past award winners, academics and leaders in the fields of product development, design, engineering, science and medical. One of the evening's many highlights was the presentation of the prestigious Edison Achievement Award to Dr. Paul E. Jacobs, chairman and CEO of Qualcomm Incorporated. The award honors innovation leaders and business executives who have made a significant and lasting contribution to innovation throughout their careers. The Edison Achievement Award serves as inspiration to future innovators and to the world at large.
In addition to the Awards Gala, the annual Edison Awards program encompassed multiple events over a two-day period including an opening reception, "Meet the Innovators Forum" and the "Innovators' Showcase", which offered guests a hands-on experience with many of the winning products.
About the Edison Awards™
The Edison Awards is a program conducted by Edison Universe, a non-profit, 501(c)(3) organization dedicated to fostering future innovators. The Awards have been recognizing and honoring the best in innovations and innovators since 1987. They honor game-changing innovations that are at the forefront of new product and service development, marketing and human-centered design, and are one of the highest accolades a company can receive in the name of successful innovation. For more information about the Edison Awards complete program and a list of past winners, visit www.edisonawards.com.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and awarded a 2013 Prism Award for Innovation in Photonics. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.